170 related articles for article (PubMed ID: 36741914)
1. Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression.
Wei Z; Wang Z; Chai Q; Li Z; Zhang M; Zhang Y; Zhang L; Tang Q; Zhu H; Sui H
Exp Ther Med; 2023 Feb; 25(2):86. PubMed ID: 36741914
[TBL] [Abstract][Full Text] [Related]
2. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
5. Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells.
Zhang S; Zhang Y; Qu J; Che X; Fan Y; Hou K; Guo T; Deng G; Song N; Li C; Wan X; Qu X; Liu Y
Braz J Med Biol Res; 2017 Nov; 51(1):e6472. PubMed ID: 29160412
[TBL] [Abstract][Full Text] [Related]
6. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
7. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
8. Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p.
Zhao K; Cheng X; Ye Z; Li Y; Peng W; Wu Y; Xing C
Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33722958
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
10. CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer.
Gao L; Xu J; He G; Huang J; Xu W; Qin J; Zheng P; Ji M; Chang W; Ren L; Wei Y; Xu J; Liang C
Am J Cancer Res; 2019; 9(11):2531-2543. PubMed ID: 31815051
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer.
Yang YN; Zhang R; Du JW; Yuan HH; Li YJ; Wei XL; Du XX; Jiang SL; Han Y
Cancer Cell Int; 2018; 18():164. PubMed ID: 30377411
[TBL] [Abstract][Full Text] [Related]
12. LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways.
Yuan HH; Zhang XC; Wei XL; Zhang WJ; Du XX; Huang P; Chen H; Bai L; Zhang HF; Han Y
J Cancer; 2022; 13(1):253-267. PubMed ID: 34976187
[No Abstract] [Full Text] [Related]
13. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
Yu M; Wang H; Zhao W; Ge X; Huang W; Lin F; Tang W; Li A; Liu S; Li RK; Jiang SH; Xue J
Theranostics; 2022; 12(9):4386-4398. PubMed ID: 35673560
[No Abstract] [Full Text] [Related]
14. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
15. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer.
Hu JL; Wang W; Lan XL; Zeng ZC; Liang YS; Yan YR; Song FY; Wang FF; Zhu XH; Liao WJ; Liao WT; Ding YQ; Liang L
Mol Cancer; 2019 May; 18(1):91. PubMed ID: 31064356
[TBL] [Abstract][Full Text] [Related]
16. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
17. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
18. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer.
Park SH; Jo MJ; Kim BR; Jeong YA; Na YJ; Kim JL; Jeong S; Yun HK; Kim DY; Kim BG; Kang SH; Oh SC; Lee DH
Theranostics; 2019; 9(8):2235-2251. PubMed ID: 31149041
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
